Literature DB >> 19711437

A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.

Brian H Kushner1, Kim Kramer, Shakeel Modak, Timothy J Akhurst, Nai-Kong V Cheung.   

Abstract

An asymptomatic 11-week-old male received no treatment after he was classified as having a suspected atypical form of MYCN-nonamplified hyperdiploid stage 4S neuroblastoma (NB), with masses in an adrenal gland, subcutaneous tissues, and the falx cerebri. Within 2 months, however, disease progressed in dura and bone marrow. Two cycles of low-dose chemotherapy achieved a partial response; treatment was discontinued. Complete remission was documented 24 weeks post-cycle 2, and has continued >6 years. The falx cerebri probably does not represent an atypical site for stage 4S NB, but stage 4 NB with favorable biology is sometimes curable with minimal therapy. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19711437      PMCID: PMC4079037          DOI: 10.1002/pbc.22243

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  18 in total

1.  Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.

Authors:  H J Nickerson; K K Matthay; R C Seeger; G M Brodeur; H Shimada; C Perez; J B Atkinson; M Selch; R B Gerbing; D O Stram; J Lukens
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  [Neuroblastoma metastasis to the falx cerebri. A case report].

Authors:  A Brunetti; E Tedeschi; G Belfiore; M Salvatore
Journal:  Radiol Med       Date:  1992-04       Impact factor: 3.469

3.  Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis?

Authors:  B Hero; T Simon; S Horz; F Berthold
Journal:  Med Pediatr Oncol       Date:  2000-12

4.  Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course?

Authors:  M Guglielmi; B De Bernardi; A Rizzo; S Federici; C Boglino; F Siracusa; A Leggio; F Cozzi; G Cecchetto; L Musi; T Bardini; A M Fagnani; G C Bartoli; A Pampaloni; D Rogers; M Conte; C Milanaccio; P Bruzzi
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

5.  Intracranial neuroblastoma.

Authors:  N R Shah; E Wilt; J S Lobel; F Mahmud; P J Cera
Journal:  Med Pediatr Oncol       Date:  1995-04

Review 6.  Why does stage 4s neuroblastoma regress spontaneously?

Authors:  J Pritchard; J A Hickman
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321

Review 7.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

8.  Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation.

Authors:  Kim Kramer; Brian H Kushner; Jeffrey C Allen; George Krol; Nai-Kong V Cheung
Journal:  J Pediatr Hematol Oncol       Date:  2004-11       Impact factor: 1.289

9.  Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.

Authors:  V Minard; O Hartmann; M C Peyroulet; J Michon; C Coze; A S Defachelle; O Lejars; Y Perel; C Bergeron; P Boutard; G Leverger; J L Stephan; A Thyss; P Chastagner; G Couillault; C Devalck; P Lutz; F Mechinaud; F Millot; D Plantaz; X Rialland; H Rubie
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

10.  Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP).

Authors:  G Schleiermacher; H Rubie; O Hartmann; C Bergeron; P Chastagner; F Mechinaud; J Michon
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.